Another Amylin investor group rebels

Now, Amylin Pharmaceuticals faces two dissident investor groups: Eastbourne Capital Management has joined Carl Icahn's group in backing a slate of director candidates, saying it has "lost confidence" in the San Diego company's management. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.